Liraglutide Effect in Atrial Fibrillation

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium.

To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Anti-Arrhythmia Agents; Liraglutide

Criteria

Inclusion Criteria:

• Male and female, age 18 or older

• Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days

• BMI ≥27 kg/m2

• Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation

• Receiving follow-up care at the University of Miami

Exclusion Criteria:

• Inability to sign an informed consent

• Patients with longstanding persistent atrial fibrillation of more than 3 years

• Prior ablation for atrial fibrillation

• Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example, hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure)

• Patients with a life expectancy <1 year

• Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks before entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

• Known contraindications to Liraglutide, such as the previous history of pancreatitis or medullary thyroid carcinoma

• Personal or family history of multiple endocrine neoplasias

• Known serious hypersensitivity reaction to Liraglutide

• Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other GLP-1 analogs, or DPP4 inhibitors

• Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy

• Poorly controlled type 2 diabetes with HbA1c > 10%

• Pregnant women

• Women who are breast-feeding or intend to become pregnant